中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
32期
17-20
,共4页
改良FOLFOX6%新辅助化疗%术后化疗%进展期胃癌
改良FOLFOX6%新輔助化療%術後化療%進展期胃癌
개량FOLFOX6%신보조화료%술후화료%진전기위암
Modified FOLFOX6%Neoadjuvant chemotherapy%Postoperative chemotherapy%Advanced gastric cancer
目的：比较改良FOLFOX6新辅助化疗与术后化疗治疗进展期胃癌的临床效果及不良反应。方法选择2009年3月~2010年6月瑞安市人民医院60例经组织学证实的局部进展期或转移性胃癌患者，分为改良FOL-FOX6新辅助化疗组(术前组)、改良FOLFOX6术后辅助化疗组(术后组)，化疗4周后进行疗效评价，观察两组临床效果、疾病进展时间、生存时间和不良反应。结果术前组总有效率及肿瘤控制率(50.0%、76.7%)均高于术后组(43.3%、70.0%)，差异有统计学意义(χ2=5.90，5.88，均P<0.05)。术前组Ⅲ~Ⅳ度不良反应发生为8例，术后组Ⅲ~Ⅳ度不良反应发生为13例，差异有统计学意义(χ2=10.76，P<0.05)。术前组肿瘤进展时间少于术后组[(10.4±2.4)个月比(16.9±1.7)个月]，2年生存率高于术后组(86.67%比66.67%)，差异有统计学意义(t =7.71，χ2=8.02，均P<0.05)。结论改良FOLFOX6新辅助化疗相对于改良FOLFOX6术后辅助化疗而言，其疗效和肿瘤进展时间、生存时间比较更佳，预期将为临床进展期胃癌的治疗提供新的高效安全的化疗方案，能有效提高进展期胃癌患者生存时间和生活质量，减少患者经济负担。
目的：比較改良FOLFOX6新輔助化療與術後化療治療進展期胃癌的臨床效果及不良反應。方法選擇2009年3月~2010年6月瑞安市人民醫院60例經組織學證實的跼部進展期或轉移性胃癌患者，分為改良FOL-FOX6新輔助化療組(術前組)、改良FOLFOX6術後輔助化療組(術後組)，化療4週後進行療效評價，觀察兩組臨床效果、疾病進展時間、生存時間和不良反應。結果術前組總有效率及腫瘤控製率(50.0%、76.7%)均高于術後組(43.3%、70.0%)，差異有統計學意義(χ2=5.90，5.88，均P<0.05)。術前組Ⅲ~Ⅳ度不良反應髮生為8例，術後組Ⅲ~Ⅳ度不良反應髮生為13例，差異有統計學意義(χ2=10.76，P<0.05)。術前組腫瘤進展時間少于術後組[(10.4±2.4)箇月比(16.9±1.7)箇月]，2年生存率高于術後組(86.67%比66.67%)，差異有統計學意義(t =7.71，χ2=8.02，均P<0.05)。結論改良FOLFOX6新輔助化療相對于改良FOLFOX6術後輔助化療而言，其療效和腫瘤進展時間、生存時間比較更佳，預期將為臨床進展期胃癌的治療提供新的高效安全的化療方案，能有效提高進展期胃癌患者生存時間和生活質量，減少患者經濟負擔。
목적：비교개량FOLFOX6신보조화료여술후화료치료진전기위암적림상효과급불량반응。방법선택2009년3월~2010년6월서안시인민의원60례경조직학증실적국부진전기혹전이성위암환자，분위개량FOL-FOX6신보조화료조(술전조)、개량FOLFOX6술후보조화료조(술후조)，화료4주후진행료효평개，관찰량조림상효과、질병진전시간、생존시간화불량반응。결과술전조총유효솔급종류공제솔(50.0%、76.7%)균고우술후조(43.3%、70.0%)，차이유통계학의의(χ2=5.90，5.88，균P<0.05)。술전조Ⅲ~Ⅳ도불량반응발생위8례，술후조Ⅲ~Ⅳ도불량반응발생위13례，차이유통계학의의(χ2=10.76，P<0.05)。술전조종류진전시간소우술후조[(10.4±2.4)개월비(16.9±1.7)개월]，2년생존솔고우술후조(86.67%비66.67%)，차이유통계학의의(t =7.71，χ2=8.02，균P<0.05)。결론개량FOLFOX6신보조화료상대우개량FOLFOX6술후보조화료이언，기료효화종류진전시간、생존시간비교경가，예기장위림상진전기위암적치료제공신적고효안전적화료방안，능유효제고진전기위암환자생존시간화생활질량，감소환자경제부담。
Objective To observe the clinical effect and adverse reaction of modified FOLFOX6 neoadjuvant chemother-apy and postoperative chemotherapy in advanced gastric cancer. Methods 60 patients with histologically proven locally advanced or metastatic gastric cancerin March 2009 to June 2010 in the People's Hospital of Rui'an City were random-ly divided into modified FOLFOX6 neoadjuvant chemotherapy group (preoperation group), chemotherapy group modified FOLFOX6 operation (postoperation group), the therapeutic effect was evaluated after 4 weeks, the clinical curative ef-fect, disease progression and survival time, adverse reaction were observed. Results The total effectiveness and tumor control rate of preoperation group were 50.0%, 76.7%, which were higher than those of postoperation group (43.3%, 70.0%), with statistical significance between the two groups (χ2=5.90, 5.88, all P<0.05). The preoperation group forⅢ-Ⅳ degree of adverse reactions were 8 cases, and the postoperation group were 13 cases, there was significant differ-ence (χ2= 10.76, P< 0.05). The tumor progression time was shorter in preoperation group than that in postoperation group [(10.4±2.4) months v s (16.9±1.7) months], and survival rate in 2 years was higher in preoperation group than that in postoperation group (86.67%v s 66.67%), there were significant differences between two groups (t =7.71,χ2=8.02, all P<0.05). Conclusion The curative effect and tumor progression,time survival time in modified FOLFOX6 neoadju-vant chemotherapy is better than the improved FOLFOX6 postoperative adjuvant, That is expected to provide efficient and safe new chemotherapy for the treatment of advanced gastric cancer, and can effectively improve survival time and quality of life and reduce the economic burden of the patients with advanced gastric cancer.
